Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): A double-blind, placebo-controlled, randomised, phase 3 trial

The Lancet

Volumn 387, Issue 10032, 2016, Pages 2008-2016

  Haas, Naomi B ^a   Manola, Judith ^b   Uzzo, Robert G ^c   Flaherty, Keith T ^d   Wood, Christopher G ^e   Kane, Christopher ^f   Jewett, Michael ^g   Dutcher, Janice P ^h   Atkins, Michael B ⁱ   Pins, Michael ^j   Wilding, George ^e   Cella, David ^k   Wagner, Lynne ^l   Matin, Surena ^e   Kuzel, Timothy M ^k   Sexton, Wade J ^m   Wong, Yu Ning ^c   Choueiri, Toni K ^b   Pili, Roberto ⁿ   Puzanov, Igor ^o   Kohli, Manish ^p   Stadler, Walter ^q   Carducci, Michael ^r   Coomes, Robert ^s   Dipaola, Robert S ^t   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

^h Cancer Research Foundation   (United States)

ⁱ GEORGETOWN UNIVERSITY   (United States)

^j UNIVERSITY OF ILLINOIS   (United States)

^k NORTHWESTERN UNIVERSITY   (United States)

^l WAKE FOREST SCHOOL OF MEDICINE   (United States)

^m H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁿ INDIANA UNIVERSITY   (United States)

^o VANDERBILT INGRAM CANCER CENTER   (United States)

^p MAYO CLINIC   (United States)

^q UNIVERSITY OF CHICAGO   (United States)

^r JOHNS HOPKINS UNIVERSITY   (United States)

^s Cancer Research Patient Advocate   (United States)

^t RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; INDOLE DERIVATIVE; NICOTINAMIDE; PYRROLE DERIVATIVE;

ADULT; AGED; ANOREXIA; ARTICLE; CANADA; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RECURRENCE; COLITIS; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG FATALITY; DYSPEPSIA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART FUNCTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY FUNCTION; LIVER FUNCTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; STOMACH PERFORATION; STOMATITIS; SURGICAL APPROACH; UNITED STATES; VOMITING; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; CLINICAL TRIAL; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; KIDNEY NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRROLES; TREATMENT OUTCOME;

EID: 84959932876     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)00559-6     Document Type: Article

References (31)

1. International Agency for Research on Cancer GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 http://globocan.iarc.fr/Pages/fact-sheets-population.aspx (accessed Dec 2, 2015).
2. A Zisman, AJ Pantuck, F Dorey et al. Improved prognostication of renal cell carcinoma using an integrated staging system J Clin Oncol 19 2001 1649 1657
3. BC Leibovich, JC Cheville, CM Lohse et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials J Urol 174 2005 1759 1763
4. M Sorbellini, MW Kattan, ME Snyder et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma J Urol 173 2005 48 51
5. S Pal, NB Haas Adjuvant therapy for renal cell carcinoma: past, present, and future Oncologist 19 2014 851 859
6. B Escudier, T Eisen, WM Stadler et al. Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
7. RJ Motzer, TE Hutson, P Tomczak et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
8. C Coppin, C Kollmannsberger, L Le, F Porzsolt, T Wilt Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials BJU Int 108 2011 1556 1563
9. RJ Motzer, TE Hutson, D Cella et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma N Engl J Med 369 2013 722 731
10. JS Lam, O Shvarts, JT Leppert, AJ Pantuck, RA Figlin, AS Belldegrun Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system J Urol 174 2005 466 472
11. NB Haas, J Manola, B Ky et al. Effects of adjuvant sorafenib and sunitinib on cardiac function in renal cell carcinoma patients without overt metastases: results from ASSURE, ECOG 2805 Clin Cancer Res 21 2015 4048 4054
12. C Jennison, BW Turnbull Interim analyses: the repeated confidence interval approach J R Stat Soc Series B Stat Methodol 51 1989 305 334
13. JR Gnarra, K Tory, Y Weng et al. Mutations of the VHL tumour suppressor gene in renal carcinoma Nat Genet 7 1994 85 90
14. CN Sternberg, ID Davis, J Mardiak et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
15. BI Rini, B Escudier, P Tomczak et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 2011 1931 1939
16. BI Rini, S Halabi, JE Rosenberg et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 2008 5422 5428
17. LB Saltz, S Clarke, E Diaz-Rubio et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
18. K Miller, M Wang, J Gralow et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2007 2666 2676
19. A Sandler, R Gray, MC Perry et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
20. CJ Allegra, G Yothers, MJ O'Connell et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial J Clin Oncol 31 2013 359 364
21. D Cameron, J Brown, R Dent et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial Lancet Oncol 14 2013 933 942
22. DR Spigel, JD Hainsworth, DA Yardley et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab J Clin Oncol 28 2010 43 48
23. ML Veronese, A Mosenkis, KT Flaherty et al. Mechanisms of hypertension associated with BAY 43-9006 J Clin Oncol 24 2006 1363 1369
24. BP Rini, DP Cohen, DR Lu et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 103 2011 763 773
25. JML Ebos, CR Lee, W Cruz-Munoz, G Bjarnason, JG Christensen, RS Kerbel Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 2009 232 239
26. R Schor-Bardach, DC Alsop, I Pedrosa et al. Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology 25 2009 731 742
27. JR van Beijnum, P Nowak-Sliwinska, EJ Huijbers, VL Thijssen, AW Griffioen The great escape; the hallmarks of resistance to antiangiogenic therapy Pharmacol Rev 67 2015 441 461
28. JM Ebos, CR Lee, JG Christensen, AJ Mutsaers, RS Kerbel Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy Proc Natl Acad Sci USA 104 2007 17069 17074
29. AW Griffioen, LA Mans, AM de Graaf et al. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients Clin Cancer Res 18 2012 3961 3971
30. HJ Hammers, HM Verheul, B Salumbides et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study Mol Cancer Ther 9 2010 1525 1535
31. LH Schwartz, M Mazumdar, L Wang et al. Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials Cancer 98 2003 1611 1619